Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
For the nine months, sales was CAD 0.81571 million. Revenue was CAD 0.83196 million compared to CAD 0.023274 million a year ago. Net loss was CAD 2.68 million compared to CAD 6.58 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.06 a year ago.